ADC Therapeutics provides business updates

ADC Therapeutics provided business updates. Recent Highlights and Developments: ZYNLONTA net sales for the fourth quarter of 2023 are expected to be approximately $16.5 million. The Phase 1 LOTIS-7 trial of ZYNLONTA in combination with bispecifics glofitamab or mosunetuzumab is actively enrolling patients. The dose-limiting toxicity (DLT) period has been cleared for the first dosing level of ZYNLONTA 90 microgram/kg in both arms. An oral presentation at the American Society of Hematology 2023 Annual Meeting from the University of Miami investigator-initiated trial exploring ZYNLONTA in combination with rituximab in high-risk relapsed or refractory FL indicated a best overall response rate of 96.3% and a complete response rate of 85.2%. Pipeline: ADCT-601: In the Phase 1b trial, the maximum-tolerated dose has been reached, and the study is currently in dose optimization. ADCT-901: The Company has decided to discontinue this program due to limited signs of efficacy in the dose escalation phase and to reallocate capital to prioritized programs. ADCT-602: Dose escalation and expansion in the Phase 1 trial is progressing, and additional clinical trial sites are being added to accelerate enrollment. Early-stage pipeline: The Company is advancing a portfolio of investigational ADCs including those targeting Claudin-6, NaPi2b and PSMA. Guidance: The Company expects the following based on its current business plan: Decrease in total operating expenses expected in full year 2023 and 2024 as compared to 2022; Cash runway expected into 4Q 2025; Expected Milestones in 2024